Magnetic collars improve owner-reported pain scores in dogs with osteoarthritis in a blinded crossover study.

Objective: To investigate changes in owner-reported pain, interference of pain on function, and quality of life (QOL) in dogs with clinically suspected osteoarthritis when wearing a collar containing a static magnet.

Animals: 16 dogs over 5 years old weighing between 10 and 40 kg with a clinical diagnosis of osteoarthritis and on stable treatment.

Methods: A prospective, blinded crossover study in which dogs wore a collar containing a static magnet or placebo for two 4-week study arms separated by a 2-week washout period.

Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors.

Background: Angiotensin-converting enzyme inhibitors (ACEi) are a recommended treatment for glomerular proteinuria. Frequency of response to ACEi and the association of achieving proposed urine protein-to-creatinine ratio (UPC) targets on survival is unknown.

Objectives: To determine response rates to ACEi therapy and whether a positive response is associated with improved survival.

The relationships between sediment findings and culture results and the presence of proteinuria in canine urine samples.

Objectives: To assess relationships between urine sediment and microbial culture findings and the presence of proteinuria in canine urine samples, and to assess the change in the percentage of proteinuric samples and urine protein-to-creatinine ratio when urine abnormalities resolve.

Materials And Methods: Canine urine samples collected via cystocentesis and submitted for culture and contemporaneous urinalysis (including urine protein-to-creatinine ratio) were retrospectively identified. Dogs receiving corticosteroids were excluded.

Low serum folate concentrations in dogs with non-associative immune-mediated haemolytic anaemia.

Background: Folate deficiency in people can occur in conditions causing increased demand, including haemolytic anaemia. This has not been investigated in dogs with non-associative immune-mediated haemolytic anaemia (IMHA).

Methods: Cohort study of 15 dogs with non-associative IMHA.

Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019).

Objectives: To describe the incidence, severity and progression of proteinuria over the first 6 months of masitinib treatment in tumour-bearing dogs without pre-existing proteinuria. To describe the effect of treatment on urine protein:creatinine and renal parameters in patients with pre-existing proteinuria.

Materials And Methods: Records were reviewed from patients receiving masitinib for neoplasms between June 1, 2010, and May 5, 2019.